ERBB2 and breast carcinoma: Furthermore, in an online dataset of HER2+ breast cancer patients treated with a neoadjuvant trastuzumab-containing regimen (trastuzumab + paclitaxel) (GSE62327; n = 24)38, six tumors with pathologic complete response (pCR) all showed higher PPP2R2B expression (Z-score −0.5 as cutoff) compared to tumors with an incomplete response (RD) where half of them showed lower expression of PPP2R2B (Fig. 1f).